Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease-Reference-Cited by-同舟云学术

Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease

Published:2022-04 Issue:13 Volume:8 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Bu Xian-Le¹²³^ORCID,Sun Pu-Yang¹³^ORCID,Fan Dong-Yu¹³⁴^ORCID,Wang Jun¹³^ORCID,Sun Hao-Lun⁴,Cheng Yuan¹³^ORCID,Zeng Gui-Hua¹³,Chen Dong-Wan¹³,Li Hui-Yun¹³,Yi Xu¹³,Shen Ying-Ying¹³^ORCID,Miles Luke A.⁵^ORCID,Maruff Paul⁵⁶^ORCID,Gu Ben J.⁵^ORCID,Fowler Christopher J.⁵^ORCID,Masters Colin L.⁵^ORCID,Wang Yan-Jiang¹²³⁷⁸^ORCID

Affiliation:

1. Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.

2. Institute of Brain and Intelligence, Third Military Medical University, Chongqing, China.

3. Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China.

4. Shigatse Branch, Xinqiao Hospital, Third Military Medical University, Shigatse, China.

5. The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.

6. CogState, Melbourne, Victoria, Australia.

7. State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing, China.

8. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.

Abstract

CD22 has been suggested to contribute to Alzheimer’s disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. Soluble CD22 (sCD22) generated by cleavage from cell membranes may be a marker of inflammation and microglial dysfunction; but alterations of sCD22 levels in AD and their correlation with AD biomarkers remain unclear. Plasma sCD22 levels were measured in cognitively normal non-AD participants and patients with preclinical AD and AD dementia from a Chinese cohort and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Plasma sCD22 levels were elevated in patients with preclinical and dementia AD. Plasma sCD22 levels were negatively correlated with cerebrospinal fluid (CSF) Aβ42 levels and Aβ42/Aβ40, and positively correlated with CSF phosphorylated tau levels and brain Aβ burden, but negatively correlated with cognitive function. Moreover, higher plasma sCD22 levels were associated with faster cognitive decline during follow-up. These findings suggest that CD22 plays important roles in AD development, and that sCD22 is a potential biomarker for AD.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference31 articles.

1. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

2. Über eine eigenartige Erkrankung der Hirnrinde;Alzheimer A.;Allg. Z. Psych. Psych.-gerich. Med.,1907

3. Amyloid plaque core protein in Alzheimer disease and Down syndrome.

4. Microglia: Immune and non-immune functions

5. Microglia in Alzheimer’s disease

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Diagnostic Potential of Circulating Autoantibodies to Amyloid-β in Alzheimer’s Disease;Journal of Alzheimer's Disease;2023-07-18

2. Looking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy;Exploration of Neuroprotective Therapy;2023-06-30

3. Development and validation of a 13-gene signature associated with immune function for the detection of Alzheimer's disease;Neurobiology of Aging;2023-05

4. Roles of Siglecs in neurodegenerative diseases;Molecular Aspects of Medicine;2023-04

5. Exploring the Associations between Alzheimer’s Disease and GBM Mediated by Microglia Based on Network Analysis;The Journal Of Prevention of Alzheimer's Disease;2023